Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels.

Plasma high density lipoprotein (HDL) levels are strongly genetically determined and show a general inverse relationship with coronary heart disease (CHD). The cholesteryl ester transfer protein (CETP) mediates the transfer of cholesteryl esters from HDL to other lipoproteins and is a key participant in the reverse transport of cholesterol from the periphery to the liver. A high prevalence of two different CETP gene mutations (D442G, 5.1%; intron 14G:A, 0.5%), was found in 3,469 men of Japanese ancestry in the Honolulu Heart Program and mutations were associated with decreased CETP (-35%) and increased HDL chol levels (+10% for D442G). However, the overall prevalence of definite CHD was 21% in men with mutations and 16% in men without mutations. The relative risk (RR) of CHD was 1.43 in men with mutations (P < .05); after adjustment for CHD risk factors, the RR was 1.55 (P = .02); after additional adjustment for HDL levels, the RR was 1.68 (P = .008). Similar RR values were obtained for the D442G mutation alone. Increased CHD in men with mutations was primarily observed for HDL chol 41-60 mg/dl; for HDL chol > 60 mg/dl men with and without mutations had low CHD prevalence. Thus, genetic CETP deficiency appears to be an independent risk factor for CHD, primarily due to increased CHD prevalence in men with the D442G mutation and HDL cholesterol between 41 and 60 mg/dl. The findings suggest that both HDL concentration and the dynamics of cholesterol transport through HDL (i.e., reverse cholesterol transport) determine the anti-atherogenicity of the HDL fraction.

[1]  S. Kihara,et al.  Atherosclerotic disease in marked hyperalphalipoproteinemia. Combined reduction of cholesteryl ester transfer protein and hepatic triglyceride lipase. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[2]  E. Rubin,et al.  Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene. , 1995, The Journal of clinical investigation.

[3]  K. Williams,et al.  The response-to-retention hypothesis of early atherogenesis. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[4]  S. Horiuchi,et al.  Structural and functional differences of subspecies of apoA-I-containing lipoprotein in patients with plasma cholesteryl ester transfer protein deficiency. , 1995, Journal of lipid research.

[5]  C. Fielding,et al.  Molecular physiology of reverse cholesterol transport. , 1995, Journal of lipid research.

[6]  S. Grundy,et al.  Variation at the hepatic lipase and apolipoprotein AI/CIII/AIV loci is a major cause of genetically determined variation in plasma HDL cholesterol levels. , 1994, The Journal of clinical investigation.

[7]  H. Mabuchi,et al.  Genetic cholesteryl ester transfer protein deficiency caused by two prevalent mutations as a major determinant of increased levels of high density lipoprotein cholesterol. , 1994, The Journal of clinical investigation.

[8]  E. Rubin,et al.  Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. , 1994, The Journal of clinical investigation.

[9]  S. Yamashita,et al.  A missense mutation in the cholesteryl ester transfer protein gene with possible dominant effects on plasma high density lipoproteins. , 1993, The Journal of clinical investigation.

[10]  J. Breslow Transgenic mouse models of lipoprotein metabolism and atherosclerosis. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[11]  A. Tall,et al.  Hypertriglyceridemia and cholesteryl ester transfer protein interact to dramatically alter high density lipoprotein levels, particle sizes, and metabolism. Studies in transgenic mice. , 1993, The Journal of clinical investigation.

[12]  A. Tall Plasma cholesteryl ester transfer protein. , 1993, Journal of lipid research.

[13]  K. Marotti,et al.  Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein , 1993, Nature.

[14]  J. Breslow,et al.  An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3' untranslated region polymorphisms. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[15]  W. J. Johnson,et al.  Apolipoproteins, membrane cholesterol domains, and the regulation of cholesterol efflux. , 1992, Journal of lipid research.

[16]  A. J. Valente,et al.  Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. , 1991, The Journal of clinical investigation.

[17]  R. Krauss,et al.  Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI , 1991, Nature.

[18]  A. Tall,et al.  Reduced high density lipoprotein cholesterol in human cholesteryl ester transfer protein transgenic mice. , 1991, The Journal of biological chemistry.

[19]  R. Kronmal,et al.  The Cardiovascular Health Study: design and rationale. , 1991, Annals of epidemiology.

[20]  A. Tall,et al.  Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. , 1990, The New England journal of medicine.

[21]  J. Breslow,et al.  Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice. , 1990, Science.

[22]  L. Fong,et al.  High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. , 1990, Biochimica et biophysica acta.

[23]  V. Fuster,et al.  Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. , 1990, The Journal of clinical investigation.

[24]  D. Steinberg,et al.  Prevention of low density lipoprotein aggregation by high density lipoprotein or apolipoprotein A-I. , 1990, Journal of lipid research.

[25]  A. Tall,et al.  Distribution and concentration of cholesteryl ester transfer protein in plasma of normolipemic subjects. , 1990, The Journal of clinical investigation.

[26]  D. Gordon,et al.  High-density lipoprotein--the clinical implications of recent studies. , 1989, The New England journal of medicine.

[27]  A. Tall,et al.  Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins , 1989, Nature.

[28]  N. Miller,et al.  Pathophysiology of reverse cholesterol transport. Insights from inherited disorders of lipoprotein metabolism. , 1989, Arteriosclerosis.

[29]  D. Gordon,et al.  High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. , 1989, Circulation.

[30]  S B Hulley,et al.  Risk factors for coronary heart disease in adult female twins. Genetic heritability and shared environmental influences. , 1987, American journal of epidemiology.

[31]  Daniel L. McGee,et al.  Ten-year incidence of coronary heart disease in the Honolulu Heart Program. Relationship to biologic and lifestyle characteristics. , 1984, American journal of epidemiology.

[32]  J C Christian,et al.  The NHLBI twin study of cardiovascular disease risk factors: methodology and summary of results. , 1977, American journal of epidemiology.

[33]  A Kagan,et al.  Serum lipoproteins and coronary heart disease in a population study of Hawaii Japanese men. , 1976, The New England journal of medicine.

[34]  G. Miller,et al.  PLASMA-HIGH-DENSITY-LIPOPROTEIN CONCENTRATION AND DEVELOPMENT OF ISCHÆMIC HEART-DISEASE , 1975, The Lancet.

[35]  J. Fleiss,et al.  Statistical methods for rates and proportions , 1973 .

[36]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[37]  R. Worth,et al.  Ascertainment of men of Japanese ancestry in Hawaii through World War II Selective Service registration. , 1970, Journal of chronic diseases.

[38]  G. Semenuk,et al.  The plasma lecithin: cholesterol acyltransferase reaction in normal, hypophysectomized and thyroidectomized rats and in hamsters. , 1969, Life sciences.